Skip to main content
SpringerLink
Log in

The Role of Hormonal Treatment in Prostate Cancer

  • Chapter
Prostate Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 175))

Abstract

In 1941 Huggins and Hodges published for the first time the favorable effects of surgical castration and estrogen treatment on the progression of metastatic prostate cancer. However, this hormonal therapy is not without side effects. Since this pioneering milestone in history of prostate cancer, a further tremendous innovation did not take place. Today, due to intensive clinical, biochemical, nuclear-biological and molecular- biological research, many hormone active treatment variations are available. Besides traditional hormonal therapy, surgical or chemical castration, maximal androgen blockade, nontraditional forms of hormonal therapy, intermittent hormonal therapy, antiandrogens, 5-α-reductase inhibitors, and their combinations, we discuss options toward creating an increased number of side effect-oriented offers of hormonal treatment options, guaranteeing a longer and more comfortable exhaustion of the individual hormonal period of response and probably a longer survival. The prerequisite is a closer-than-ever monitoring by tumor marker and an early observation of symptomatic changes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Allison RR, Schulsinger A, Vongtama V, Grant P, Shin KH, Huben R (1997) If you “watch and wait”, prostate cancer may progress dramatically. Int J Radiat Oncol Biol Phys 39:1019–1023

    PubMed  CAS  Google Scholar 

  • Andriole G, Lieber M, Smith J, et al (1995) Treatment with finasteride following radical prostatectomy for prostatic cancer. Urology 45:391–497

    Google Scholar 

  • Aus G, Hugosson J, Norlen L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 145:460–465

    Google Scholar 

  • Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (1998) Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 159:2013–2016

    PubMed  CAS  Google Scholar 

  • Aus G, Abbou CC, Bolla M, Heidenreich A, van Poppel H, Schmid HP, Wolff JM, Zattoni F (2005) Guidelines on prostate cancer. Eur Urol 48:546–551

    PubMed  CAS  Google Scholar 

  • Bader P, Burkhard FC, Markwalder R, Studer UF (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854

    PubMed  Google Scholar 

  • Bagshaw MA, Cox RS, Ray GR (1988) Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 7:47–60

    PubMed  Google Scholar 

  • Bales CT, Chodak GW (1996) A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47(Suppl 1A):38–43

    PubMed  CAS  Google Scholar 

  • Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED (2003) Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 62:872–876

    PubMed  Google Scholar 

  • Bennett CL, Tosteson TD, Schmitt B, et al (1999) Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer. a meta-analysis of nine published randomized controlled trials and 4128 patients using fluamide. Prostate Cancer Prostatic Dis 2:4–8

    PubMed  Google Scholar 

  • Bertagna C, de Géry A, Hucher M, Francois JP, Zanirato J (1994) Efficacy of combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 73:396–402

    PubMed  CAS  Google Scholar 

  • Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Torecilla JL, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–108

    PubMed  CAS  Google Scholar 

  • Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res 50:2275–2282

    PubMed  CAS  Google Scholar 

  • Byar DP (1972) Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of consevative treatment. J Urol 24:485–488

    Google Scholar 

  • Byar DP (1973) Proceedings: the veterans administration co-operative urological research group studies of cancer of the prostate. Cancer 32:1126–1130

    PubMed  CAS  Google Scholar 

  • Caubet JF, Tosteson TD, Dong EW, et al (1997) Maximum androgen blockade in advanced prostate cancer. a meta-analysis of published controlled trials using nonsteroidal antiandrogens. Urology 49:71–78

    PubMed  CAS  Google Scholar 

  • Cheng L, Zincke H, Blute ML, Bergstrahl EJ, Scherer B, Bostwick DG (2001) Risk of prostate carcinoma death in patients wit lymph node metastasis. Cancer 91:66–73

    PubMed  CAS  Google Scholar 

  • Cox JD, Gallagher MJ, Hammond EH, et al (1999) Consensus statements on radiation therapy of prostate cancer: guide-lines for prostate rebiopsy after radiation and for radiation therapy with rising prostatespecific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155

    PubMed  CAS  Google Scholar 

  • Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advancedstage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541

    PubMed  CAS  Google Scholar 

  • D’Amico AV, Moul JW, Carroll PR, et al (2003) Surrogate end point for prostate cancer-spezific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376–1383

    PubMed  Google Scholar 

  • D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6 months androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821

    PubMed  CAS  Google Scholar 

  • Davis NB, Ryan CW, Stadler WM, Vogelzang NJ (2005) A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int 96:787–790

    PubMed  CAS  Google Scholar 

  • Dawson NA (1993) Treatment of progressive metastatic prostate cancer. Oncology 7:17

    PubMed  CAS  Google Scholar 

  • De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, Debre B (2003) Intermittent androgen suppression in patients with prostate cancer. BJU Int 91:18–22

    Google Scholar 

  • de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1:163–171

    PubMed  Google Scholar 

  • Desai A, Stadler WM, Vogelzang NJ (2001) Nilutamide: possible utility as a second-line hormonal agent. Urology 58:1016–1020

    PubMed  CAS  Google Scholar 

  • Djavan B, Sesterhann I, Hruby S, Marberger M (2000) Benign prostatic glands in the surgical margin of radical retropubic prostatectomies:redefining PSA nadir. J Urol 163:A624

    Google Scholar 

  • Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, Roehl KA, Wang Z (2005) Enhancement of intermittent androgen ablation by “off-cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66:495–502

    Google Scholar 

  • Eisenberger MA, Crawford ED, Wolf M, et al (1994) Prognostic factors in stage D2 prostate cancer; important implications for future trials, results of cooperative intergroup study (INT.0036). Semin Oncol 21:613–619

    PubMed  CAS  Google Scholar 

  • Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA (1998) Bilateral orchiektomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042

    PubMed  CAS  Google Scholar 

  • Fenton MA, Shuster TD, Fertis A, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP (1997) Anti-androgen activation of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3:1383

    PubMed  CAS  Google Scholar 

  • Ferro MA, Gillatt D, Symes MO, et al (1989) High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostae specific antigen to monitor response. Urology 34:134

    PubMed  CAS  Google Scholar 

  • Fossa SD, Hosbach G, Paus E (1990) Flutamide in hormone-resistant prostatic cancer. J Urol 144:1411

    PubMed  CAS  Google Scholar 

  • Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ (2002) The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95:287–295

    PubMed  Google Scholar 

  • Garnick M, Pratt C, Campion M, Shipley J, Bernardy JD (2004) Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: results of three randomized con trolled clinical studies (Abstr No. 217). Eur Urol 57

    Google Scholar 

  • Gleave ME, Goldenberg SL, Chin JL, et al (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166:500 507

    Google Scholar 

  • Gleave ME, Goldenbergh L, Chin JL, Warnes J, Saad F, Klotz L, Jewett M, Kassabian V, Chetner M, Dupont C (2003) Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates (Abstr No. 690). J Urol Suppl 169:179

    Google Scholar 

  • Goldenberger SL, Gleave M, Bruchovsky N (1999) The role of intermittent androgen suppression in prostate cancer. AUA Update Series vol XVIII. Lesson 3:18–23

    Google Scholar 

  • Granfors T, Modig H, Damber JE, Tomic R (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or whithout pelvic lymph node involvement: a prospective randomized study. J Urol 159:2030–2034

    PubMed  CAS  Google Scholar 

  • Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL (2005) A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 174:796

    Google Scholar 

  • Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978

    PubMed  CAS  Google Scholar 

  • Horton J, Rosenbaum C, Cummings FJ (1988) Tamoxifen in advanced prostate cancer: an ECOG pilot study. Prostate 12:173–177

    PubMed  CAS  Google Scholar 

  • Horwitz EM, Winter K, Hanks GE, Lawton CA, Russel AH, Machtay M (2001) Subset analysis of RTOG 85–31 and 86–10 indicates an advantage for longterm vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49:947–956

    PubMed  CAS  Google Scholar 

  • Hsu CY, Joniau S, Van Poppel H (2005) Radical prostatectomy for locally advanced prostate cancer: technical aspects of radical prostatectomy. EAU Update Series 3:90–97

    Google Scholar 

  • Hu X, Lazar MA (2000) Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab 11:6–10

    PubMed  CAS  Google Scholar 

  • Huggins C, Hodges C (1941) Studies on prostatic cancer, effect of castration of estrogen and of androjen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    CAS  Google Scholar 

  • Isaacs JT (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26:263–273

    PubMed  CAS  Google Scholar 

  • Iversen P (2005) EPC: third analysis of bicalutamide in early prostate cancer. ECCO, Paris

    Google Scholar 

  • Iversen P, Tyrrell CJ, Kaisary AV, et al (2000) Bicalutamide (‘asodex’) 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years’ follow-up. J Urol 164:1579–1582

    PubMed  CAS  Google Scholar 

  • Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K, Scandinavian Prostatic Cancer Group (2004) Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-years median followup from the Scandinavian prostate cancer group study number 6. J Urol 172:1871–1876

    PubMed  Google Scholar 

  • Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NHA, Zagars GK, Meistrich M, Pollack A (1997) Supraadditive apoptotic response of R3327-G-rat prostate tumours to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38:1071–1077

    PubMed  CAS  Google Scholar 

  • Jordan WP, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic cancinoma. South Med J 70:1411–1413

    PubMed  Google Scholar 

  • Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvebag G, DeWolf W, Balk S, Taplin ME, Bubley GJ (1998) High dose Bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159:149–153

    PubMed  CAS  Google Scholar 

  • Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T (2001) Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 4:196–203

    PubMed  CAS  Google Scholar 

  • Kantoff PW, Halabi S, Conaway M, Picus J, et al (1996) Hydrocortisone with and eithout mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol 17:2506

    Google Scholar 

  • Kassouf W, Tanguay S, Aprikian AG (2003) Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169:1742–1744

    PubMed  CAS  Google Scholar 

  • Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J, Schröder F (1999) Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 40:105–114

    PubMed  CAS  Google Scholar 

  • Kirk D (2000) Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 86(suppl 3):220

    Google Scholar 

  • Klotz L, Schellhammer P, Carroll K (2004) A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 93:1177–1182

    PubMed  CAS  Google Scholar 

  • Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H (2004) Alternative antiandrogens to treat prostate cancer relaps after initial hormone therapy. J Urol 171:679–683

    PubMed  CAS  Google Scholar 

  • Kolvenbag GJ, Furr BJ, Blackledge GR (1998) Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1:307–314

    PubMed  CAS  Google Scholar 

  • Kuil CW, Berrevoets CA, Mulder E (1995) Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270:2569–2576

    Google Scholar 

  • Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW (1999) Intermittent complete androgen blockage in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35(suppl 1):27–31

    PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A, et al (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833

    PubMed  CAS  Google Scholar 

  • Labrie F, Cusan L, Gomez JL, Diamone P, Suburu R, Leenay M, Tetu B, Fradet B, Cansas B (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomised trial of neoadjuvant combination therapiy with flutamide and a luteinizing hormone-releasing agonist. Urology 44:29–37

    Google Scholar 

  • Lane TM, Ansell W, Farrugia D, Wilson P, Chinegwundoh F, Philp T, Hines J, Oliver RT (2004) Longterm outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol int 73:117–122

    PubMed  CAS  Google Scholar 

  • Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85–31). Int J Radiat Oncol Biol Phys 38:931–939

    PubMed  CAS  Google Scholar 

  • Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al (2001) Update results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946

    PubMed  CAS  Google Scholar 

  • Leibowitz RL, Tucker SJ (2001) Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 6:177–182

    PubMed  CAS  Google Scholar 

  • Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Sommerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HL (2004) American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:1–15

    Google Scholar 

  • Marhefka CA, Moore BM, Bishop TC, et al (2001) Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem 44:1729–1740

    PubMed  CAS  Google Scholar 

  • McLeod DG (1993) Antiandrogenic drugs. Cancer 71:1046–1049

    PubMed  CAS  Google Scholar 

  • McLeod DG, Crawford ED, DeAntoni EP (1997) Combined androgen blockade: the gold standard for metastatic prostate cancer (suppl). Eur Urol 32:70–77

    PubMed  CAS  Google Scholar 

  • ]Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostate cancer, initial results of the Medical Research Council trial. Br J Urol 79:235–246

    Google Scholar 

  • Messing EM, Manola J, Sarosdy M, Wilding G, Crawfort ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781–1788

    PubMed  CAS  Google Scholar 

  • Miyake H, Hara I, Eto H (2005) Clninical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone refractory prostate cancer. BJU Int 96:791–795

    PubMed  CAS  Google Scholar 

  • Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163:1632–1642

    PubMed  CAS  Google Scholar 

  • Moul JW, Harding P, Crawfort ED, McLeod DG (1998) Combination flutamide and finasteride in PSA-only recurrence after pior local prostate cancer therapy. J Urol 159 Suppl 9:130 (Abstr 491)

    Google Scholar 

  • Moul JW, Wu H, Sun L, et al (2004) Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141–1147

    PubMed  Google Scholar 

  • Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM (1992) Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol 147:910–915

    PubMed  CAS  Google Scholar 

  • Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK (2005) Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 96:783–786

    PubMed  Google Scholar 

  • Ockrim JL, lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, et al (2004) Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 172:2203

    PubMed  CAS  Google Scholar 

  • Ockrim JL, Lalani EN, Kakkar AK, Abel PD (2005) Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174:527–533

    PubMed  CAS  Google Scholar 

  • Olea N, Sakabe K, Soto AM, Sonnenschein C (1990) The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126:1457–1463

    PubMed  CAS  Google Scholar 

  • Paul R, Alschibaja M, van Randenborgh H, Hartung R, Breul J (2001) Neoadjuvante Hormontherapie des lokalisierten Prostatakarzinoms vor kurativer radikaler Prostatektomie—Vorteil oder Nachteil? Aktuelle Urologie 32:1–8

    Google Scholar 

  • Pether M, Goldenberger SL (2004) Intermittent androgen suppression. BJU Int 93:258–261

    PubMed  CAS  Google Scholar 

  • Petrylak DP, Tangen CM, Hussain MH, et al (2004) Cocetaxel and estramustine compared with mitoxantrone and prednisone for advanced prostate cancer. N Engl J Med 351:1513–1520

    PubMed  CAS  Google Scholar 

  • Peyromaure M, Delongchamps NB, Debré B, Zerbib M (2005) Intermittent Androgen Deprivation for biological recurrence after radical prostatectomy: long-term experience. Urology 65:724–729

    PubMed  Google Scholar 

  • Pilepich MV, Caplan R, Byhard RW, Lawton Ca, Gallagher MJ, Mesic JB, et al (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85–31. J Clin Oncol 15:1013–1021

    PubMed  CAS  Google Scholar 

  • Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252

    PubMed  CAS  Google Scholar 

  • Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkow H, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285–1290

    PubMed  CAS  Google Scholar 

  • Potosky AL, Knopf K, Clegg LX, et al (2001) Qualityof-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19:3750–3757

    PubMed  CAS  Google Scholar 

  • Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephanson RA, Albertsen PC, Gilliland FD, Stanford JL (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94:430–437

    PubMed  Google Scholar 

  • Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh P (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597

    PubMed  CAS  Google Scholar 

  • Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Valancien G (2003) A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43:233–240

    PubMed  Google Scholar 

  • Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355:1491–1498

    Google Scholar 

  • Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17:127

    PubMed  CAS  Google Scholar 

  • Rocklitz CF, Damon LE, Russi MB, et al (1988) Cytotoxicity of Ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 21:319

    Google Scholar 

  • Ryan CJ, Small EJ (2005) Secondary hormonal manipulation in prostate cancer. Curr Oncol Rep 7:228–233

    PubMed  CAS  Google Scholar 

  • Sartor O, Cooper M, Weinberger M, et al (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86:222

    PubMed  CAS  Google Scholar 

  • Sato N, Gleave ME, Bruchowsky N, Rennie PS, Goldenberg SL, Lange PH, et al (1996) Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58:139–146

    PubMed  CAS  Google Scholar 

  • Schellhammer P, Venner P, Haas G, et al (1997) Prostate specific antigen decreases after withdrawal of androgen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157:1731–1735

    PubMed  CAS  Google Scholar 

  • Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566

    PubMed  CAS  Google Scholar 

  • Scher HI, Liebertz C, Kelly WK, et al (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928

    PubMed  CAS  Google Scholar 

  • Schmitt B, Bennett CL, Seidenfeld J, Samson DJ, Wilt TJ (2000) Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2:D001526

    Google Scholar 

  • Schulmann CC, Debruyne FM, Forster G, et al (2000) 4 year follow-up results of a European prospective randomised study on neoadjuvant hormonal therapy prior to radical treatment of Prostate Cancer. Eur Urol 38:706–713

    Google Scholar 

  • Sciarra A, Di Chiro C, Di Silverio F (2000) Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 18:392–400

    PubMed  CAS  Google Scholar 

  • Seay TM, Blute ML, Zincke H (1998) Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 159:357–364

    PubMed  CAS  Google Scholar 

  • See WA, McLeod D, Iversen P, Wirth M (2001) The bicalutamide early prostate cancer program: demography. Urol Oncol 6:43–47

    PubMed  Google Scholar 

  • Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown C, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment No. 4 AHCPR Publication No. 99-E0012. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville

    Google Scholar 

  • Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL (2005) A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 96:985–989

    PubMed  Google Scholar 

  • Small EJ, Baron AD, Fippin L, et al (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 159:1204

    Google Scholar 

  • Small EJ, Halabi S, Dawson NA, et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-dependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033

    PubMed  CAS  Google Scholar 

  • Soloway MS, Schellhammer PF, Sharifi R, et al (2000) Bicalutamide and flutamide, each in combination with luteinizing hormone-releasing hormone analogs, in advanced prostate cancer: exploratory analysis of impact of extent of disease by bone scan on outcome. Prostate J 2:137–145

    Google Scholar 

  • Soloway MS, Pareek K, Sharifi R, et al (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5 year results. Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 167:112

    PubMed  Google Scholar 

  • Strum SB, Scholz MC, McDermed JE (2000) Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 5:45–52

    PubMed  CAS  Google Scholar 

  • Tannock IF, Osoba D, Stockler MR, et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a cancadian randomised trial with palliative end points. J Clin Oncol 14:1756

    PubMed  CAS  Google Scholar 

  • Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata G, Keer H, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393

    PubMed  CAS  Google Scholar 

  • Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK (2004) Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 15:974–978

    PubMed  Google Scholar 

  • Taylor CD, Elson P, Trump DL (1993) Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11:2167–2172

    PubMed  CAS  Google Scholar 

  • Tyrrell CJ, Kaisary AV, Iversen P, et al (1998) A randomised comparison of ‘asodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447–456

    PubMed  CAS  Google Scholar 

  • Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, “Casodex” Early Prostate Cancer Trialists’ Group (2005) Bicalutamide (‘asodex’) 150 mg as adjuvant to radiotherapy in patients with localized or locally advanced prostate cancer: results from the randomized Early Prostate Cancer Programme. Radiother Oncol 1:4–10

    Google Scholar 

  • Van Poppel H (2005) Surgery for clinical T3 Prostate Cancer. Eur Urol (suppl) 4:12–14

    Google Scholar 

  • Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackert P, Oyen R, Pittomvils G, Beart L (1995) Members of the belgian urooncological study group. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margines in stage T2 prostate cancer: interim result of a prospective randomized trial. J Urol 154:429–434

    PubMed  Google Scholar 

  • Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmber C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401

    PubMed  CAS  Google Scholar 

  • Wang LG, Mencher SK, McCarron JP, Ferrari AC (2004) The biological basis for the use of an antiandrogen and 5-α-reductase inhibitor in the treatment of recurrent prostate cancer: case report and review. Oncol Rep 11:1325–1329

    PubMed  CAS  Google Scholar 

  • Ward JF, Slezak JM, Blute ML, Bergstrahl EJ, Zincke H (2005) Radical prostatectomy for locally advanced (cT3) prostate cancer since the advent of prostatespecific antigen testing: 15-year outcome. BJU Int 95:751–756

    PubMed  Google Scholar 

  • Warde P (1995) Phase III randomized trial comparing total androgen blockade versus total androgen blockade plus pelvic irradiation in clinical stage T3-4, N0, M0 adenocarcinoma of the prostate. Intergroup (NCIC, CTG, CUOG, ECOG, CALGB, SWOG). National Cancer Institute of Canada Clinical Trials Group

    Google Scholar 

  • Wei JT, Gross M, Jaffe Ca, et al (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54:607–611

    PubMed  CAS  Google Scholar 

  • Wijburg C, Boeken-Kruger AE, van der Cruijsse I, Schröder FH (1999) Immediate or delayed endocrine treatment for lymphnode metastasized prostate cancer, is there a best choice? J Urol 161(4S):1149

    Google Scholar 

  • Wilkinson S, Chodak G (2004) An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 45:581–584

    PubMed  CAS  Google Scholar 

  • Wirth M, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Bicalutamide (‘asodex’) 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer. results from the second analysis of the Early Prostate Cancer program at 5,4 years’ median follow-up. J Urol 172:1865–1870

    PubMed  CAS  Google Scholar 

  • Wirth MP, Hakenberg OW, Fröhner M (2005) Therapie des lokal fortgeschrittenen Prostatakarzinoms. Urologe 44:1295–1302

    PubMed  CAS  Google Scholar 

  • Wong C, Kelce WR, Sar M, Wilson EM (1995) Androgen receptor antagonist versus agonist activities of the fungicide vinclozoline relative to hydroflutamide. J Biol Chem 270:198

    Google Scholar 

  • Zietman AL, Prince EA, Nakfoor BM, Park JJ (1997) Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38:1067–1070

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chefarzt der Klinik für Urologie, Kinderurologie und urologische Onkologie, Klinikum Saarbrücken, Winterberg 1, 66119, Saarbrücken, Germany

    Stephan H. Flüchter (Prof. Dr. med.)

  2. Klinik für Urologie, Kinderurologie und urologische Onkologie, Klinikum Saarbrücken, Winterberg 1, 66119, Saarbrücken, Germany

    Ralf Weiser FEBU (Dr. med.) & Christoph Gamper (Dr. med)

Authors
  1. Stephan H. Flüchter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf Weiser FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Gamper
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel

    Jacob Ramon MD

  2. Lange Gasthuisstraat 35-37, 2000, Antwerp, Belgium

    Louis J. Denis MD, FACS (Director Oncology Centre Antwerp Secretary Europa Uomo) (Director Oncology Centre Antwerp Secretary Europa Uomo)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Flüchter, S.H., Weiser, R., Gamper, C. (2007). The Role of Hormonal Treatment in Prostate Cancer. In: Ramon, J., Denis, L.J. (eds) Prostate Cancer. Recent Results in Cancer Research, vol 175. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-40901-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-40901-4_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40897-0

  • Online ISBN: 978-3-540-40901-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation